Fig. 5: Module matching to treatment targets to enhance therapeutic efficacy.
From: Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
a Profiling of 80 pre-treatment biopsies from patients with AD, PsO, and LP undergoing targeted therapy, separated into responders or non-responders based on clinical scoring at week 16. The dominant expression module in skin probes (Th1, Th2 or Th17) was matched to the treatment target, defined as Th2 for anti-IL4R and IL-13, Th17 for anti-IL-23 and IL-17A/F, and Th1 for JAK1/2 inhibitors. Data are represented as percentages of responding and non-responding patients in the matched and non-matched groups. b Cumulative Th1, Th2, and Th17 module scores in pre- and post-treatment biopsies in 5 non-responding AD patients undergoing anti-Th2 treatment with anti-IL4R.
